All Asia Licensing Inc. (Pink Sheets: AASI), today announced that it accepted an invitation for its chief scientist to lead a workshop September 23-25 in China at a major international conference on little-known animal diseases.
“This prestigious invitation from an arm of China’s Ministry of Agriculture is a direct result of our recently-announced Letter of Intent to enter the bio research market to test for BSE (Bovine Spongiform Encephalopathy) also known as ‘Mad Cow’ Disease,” according to Anthony Lee, CEO of All Asia Licensing.
The National Diagnostic Center for Exotic Animal Disease of China is the main sponsor of the Third OIE (Office International des Epizooties Regional Workshop and Working Group Meeting on BSE and other Prion Diseases. The conference is also co-sponsored in Qingdao, People’s Republic of China by its Animal Health and Epidemiology Center (CAHEC).
The main topics at the conference will be the control of Mad Cow Disease, Rapid Prion Testing and Prion disease diagnosis. Prions are a family of rare progressive neurodegenerative disorders.
The Letter of Intent announced between All Asia and its proposed joint venture partner is subject to change, completion of due diligence by both parties, creation of a final contract and approval of both Boards of Directors, among other things.
All Asia Licensing Inc. is a major conduit for investors to access the rapidly growing Chinese economy. By acquiring a controlling stake in unique Chinese businesses, using its contacts to work with governmental agencies, providing capital and international-minded management, the Company enables these companies to prosper in their own industries. Working with small-to-medium sized companies, All Asia assists clients by using a comprehensive suite of services of business management, consulting services and technical support through specialist networks.
“Safe Harbor Statement” Under the Private Securities Litigation Reform Act of 1995:
Certain statements in this news release are “forward-looking statements” within the meaning of the Private Securities Litigation Act of 1995. These statements include, without limitation, statements concerning the ultimate signing of a definitive contract, its impact on our future business prospects and our ability to successfully complete the commercialization of the bio research testing and grading system in China. These forward-looking statements are based on our current expectations and beliefs and are subject to a number of risk factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Such risks and uncertainties include the risks that the Letter of Intent will not lead to a successful acquisition of 50% interest in the proposed joint venture; the results we intend are not achieved; and the risks inherent in commercializing a new testing and grading system (including technology risks, market risks, financial risks and implementation risks, as well as other risks and uncertainties affecting the Company) inhibit market penetration. These risks are to be included in filings with the Securities and Exchange Commission, all of which are to be available at www.sec.gov. We disclaim any intention or obligation to revise any forward-looking statements, including, without limitation, financial estimates, whether as a result of new information, future events or otherwise.
Contacts:
Gregory A. McAndrews,
310-301-3035
Fax: 310-827-7416
greg@gregmcandrews.com
or
All
Asia Licensing Inc.
Investor Relations, +1-866-575-6854
Fax:
+1-877-420-7950
ir@allasialicensing.com
